It is with heavy hearts that we share the passing of an incredible member of our community, Ivy Elkins. Ivy made a difference in countless lives. LCRF.org/ivy

A great time discussing #ASCO24 Lung Cancer highlights with my international colleagues Alfredo Addeo MD Jarushka Naidoo. LAURA, CROWN, ADRIATIC, CM816, 77T, AEGEAN and ADC updates!

I’m very excited to announce that I have received a Susan G. Komen Career Transition Award to develop a novel antibody-drug conjugate for breast cancer immunotherapy. I’m honored to be part of this incredible breast cancer research community!

It was an honor to serve as the director of the GSBS Immunology Graduate Program during the past three years. I am extremely proud of what we accomplished, and wish the best for our new co-directors, Drs. Ekmekcioglu and Reuben. Cheers 🥂 GSBS Immunology Program MD Anderson-UTH Grad Alexandre Reuben, Ph.D.

Into the Matrix: by my friend and colleague, the amazing ⁦⁦⁦Mara Sherman Lab⁩ ! Unlocking the Secrets of the Fibrotic Fortress that Surrounds and Protects #PancreaticCancer. ⁦Memorial Sloan Kettering Cancer Center⁩ mskcc.org/news/into-matr…

Congratulations to Debbie! A great scientist, dedicated mentor, and shining example of kindness and compassion.

Happening now: ⁦Wen Jiang MD, PhD⁩ presents mechanisms into how aging affects #nanomedicine clearance and how we can improve therapeutic efficacy and decrease toxicity ⁦Nature Nano⁩ ⁦Yifan Wang, PhD⁩ ⁦MD Anderson Cancer Center⁩ ⁦Controlled Release Society⁩

Congrats, Kate! Wonderful to observe how you add value to the national cancer mission! LCRF names new Scientific Advisory Board Chair lungcancerresearchfoundation.org/lcrf-names-new…

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

Thrilled to announce our study on the novel mediator TSG-6 and its role in regulating resistance to #immunecheckpointtherapy in #cancer has been published! Special thanks to my amazing mentor Padmanee (Pam) Sharma, MD, PhD for her guidance throughout this journey! nature.com/articles/s4146…

I am proud, pleased, and relieved to announce that the Schenkel Lab’s first paper is officially published J Immunol! This has been a labor of love and I think will be an useful for many in the field! journals.aai.org/jimmunol/artic… 1/n

Beautiful talk by Francesca Citron at #cshlcancer24 ! MD Anderson Cancer Center Giulio Draetta

Huge congratulations to all my MD Anderson Cancer Center colleagues who are funded by CPRIT today. From high risk high reward awards (Wen Jiang MD, PhD) all the way to advanced spatial genomics core facility (Nicholas Navin) & everything in between! 🙌🏽 cprit.texas.gov/news-events/ar…

Congrats Wen Jiang MD, PhD !!

This photo will be in museums. (credit Todd Heisler // NYT)

Incredibly honored and humbled to receive this award, thank you AACR & GSK US! The generous 1-year term is unique and could not have come at a better time, now we dive deeply into the spatial biology of malignant progression of CRC, in rare human samples and new mouse models!

Excited for the SITC-ECI joint symposium on New Frontiers in Cancer Immunotherapy, this Sunday in Dublin☘️ Two great sessions on T cell therapies & innate immunotherapy featuring Jim Allison PhD Padmanee (Pam) Sharma, MD, PhD Join us! Society for Immunotherapy of Cancer Irish Immunology Aideen Ryan JL

Here, our Dr. Eric Singhi discusses potential areas of research interest in the treatment of patients with metastatic lung cancer: brnw.ch/21wM7D4 Eric K. Singhi, MD #LungCancer #EndCancer

#AllisonInstitute seminar starts off the year with the incredible body of work from ⁦⁦Gigi Lozano, PhD⁩ in our new home #TMC3 #StandingRoomOnly #PackedAudience ⁦James J Mancuso, PhD⁩ ⁦Jim Allison PhD⁩ ⁦Padmanee (Pam) Sharma, MD, PhD⁩ #p53

Sculpture of the Ras protein (G12C) bound to GDP and the drug Sotorasib (AMG510). The protein is half bronze and half steel with a copper seam between the two metals. Represents how the drug locks the protein in a unique conformation that blocks its function and cancer growth.